Antoni Wiedlocha funded by the EEA Poland-Norway grants
Antoni Wiedlocha
The proposal "Novel targeted therapy based on dual warhead conjugates against FGFR dependent cancers", with senior scientist Antoni Wiedlocha at Department of Molecular Cell Biology, Institute for Cancer Research, as Norwegian partner and professor Jacek Otlewski at the University of Wroclaw as Polish parther, has been awarded funding from the EEA Poland-Norway grants under the "Applied Research" programme.
Links:
From the National Centre for Research and Development in Poland:
Published in Level 2 journals, first or last author from Oslo University Hospital.
Lekva T, Frøystad M, Michelsen AE, Khan Y, Aukrust P, Halvorsen B, Roland MCP, Ueland T(2026) Circulating MALAT1 in Preeclampsia and Association With Cardiometabolic Risk Hypertension(in press) DOI 10.1161/HYPERTENSIONAHA.125.26379, PubMed 41498149
Dukefoss HB, Andresen K, Harbo M, Hasselberg NE, Grødem H, Korsæth T, Romundstad H, Moe KKW, Løvstakken L, Gude E, Dahl TB, Bjørnstad JL, Halvorsen B, Fiane AE, Broch K, Sjaastad I, Edvardsen T, Espe EKS(2026) Validation of shear wave elastography for assessing myocardial fibrosis in patients with end-stage heart failure Eur Heart J Cardiovasc Imaging(in press) DOI 10.1093/ehjci/jeaf375, PubMed 41490714
Ghiasvand R(2026) High-Risk Stage II Melanoma: AJCC Staging anomaly or understaging dilemma? Br J Dermatol(in press) DOI 10.1093/bjd/ljaf523, PubMed 41483011